Pharma Should Share Drug Targets With NIH, Sanofi-Aventis Exec Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Manufacturers should look for partnerships with the government to improve the level of innovation, Sanofi-Aventis Head of Integrated Markets O’Neil tells The Economist roundtable. Firms should partner with payors early to head off “functional equivalence” decisions.
You may also be interested in...
Rx Industry’s Mission Will Change Under Medicare, Scully Declares
Pharmaceutical companies have no idea “how massive the changes that are coming for prescription drugs are,” the former CMS administrator says. The new test for a product’s success will be “what’s Medicare going to pay for it?”
Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.
RiskMAP Guidance Includes Plans For A Website
FDA is planning to develop a Risk Minimization Action Plan website, an agency risk management guidance states